Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer

NCT ID: NCT02540356

Last Updated: 2021-01-12

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-11-02
• Study Completion Date: 2016-05-26

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of BAX69 monotherapy given either as intraperitoneal (IP) infusion (Single-Route Arm); or as IP infusion after intravenous (IV) infusion (IV+IP) (Double-Route Arm), and to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for each Arm separately, in subjects with refractory ovarian cancer and recurrent malignant ascites. In both Arms, the plasma pharmacokinetics (PK) of BAX69 will be characterized, and pharmacodynamics (PD) markers will be explored in plasma and ascites. Two expansion cohorts will further assess the tolerability of the RP2D and explore clinical signs of efficacy.

Conditions

Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single-Route Arm

BAX69 administered weekly by intraperitoneal (IP) infusion only

Group Type: EXPERIMENTAL

BAX69 Single-Route Arm

Intervention Type: BIOLOGICAL

Intraperitoneal (IP) only

Double-Route Arm

BAX69 administered weekly by intravenous (IV) infusion + intraperitoneal (IP) infusion

Group Type: EXPERIMENTAL

BAX69 Double-Route Arm

Intervention Type: BIOLOGICAL

Intravenous (IV) infusion + intraperitoneal (IP) infusion

Interventions

BAX69 Single-Route Arm

Intraperitoneal (IP) only

Intervention Type: BIOLOGICAL

BAX69 Double-Route Arm

Intravenous (IV) infusion + intraperitoneal (IP) infusion

Intervention Type: BIOLOGICAL

Other Intervention Names

Macrophage Migration Inhibitory Factor Antibody (Anti-MIF); Imalumab; Imalumab; Macrophage Migration Inhibitory Factor Antibody (Anti-MIF)

Eligibility Criteria

Inclusion Criteria

1. Provision of a signed informed consent

2. Female participants of non-childbearing potential, ≥18 years of age

3. Anticipated life expectancy >3 months at the time of screening

4. Metastatic ovarian epithelial cancer that are platinum-resistant, and has no better option available in the investigator's opinion

5. Recurrent symptomatic malignant ascites having required at least 2 paracenteses within a 45-day interval prior to baseline paracentesis

6. Participants who have an indwelling draining IP catheter (to be drained only under medical supervision)

7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2

8. Adequate hematological function, defined as:

• Platelet count ≥100,000/μL
• Prothrombin time (PT) and activated partial thromboplastin time (aPTT) <1.5 times the upper limit of normal (ULN)
• Absolute neutrophil count ≥1,000/μL
• Hemoglobin ≥9 g/dL, without the need for transfusion in the 2 weeks prior to screening

9. Adequate renal function, defined as serum creatinine ≤2.0 times ULN and creatinine clearance >50 mL/min or estimated glomerular filtration rate (eGFR) >50 mL/min/1.73 m^2

10. Adequate liver function, defined as:

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times ULN for participants without liver metastases, or ≤5 times ULN in the presence of liver metastases
• Bilirubin ≤2.0 times ULN, unless participant has known Gilbert's syndrome

11. Adequate venous access

12. Participant is willing and able to comply with the requirements of the protocol

Exclusion Criteria

1. Known central nervous system metastasis that is unstable within the last 2 months

2. Prior malignancy within the past 3 years, with the exception of curatively treated basal or squamous cell carcinoma of the skin, ductal carcinoma in situ of breast, in situ cervical carcinoma, and superficial bladder cancer

3. Residual AEs >Grade 2 from previous treatment

4. Myocardial infarction within 6 months prior to C1D1 treatment, and/or prior diagnoses of congestive heart failure (New York Heart Association Class III or IV), unstable angina, unstable cardiac arrhythmia requiring medication; and/or the participant is at risk for polymorphic ventricular tachycardia (eg, hypokalemia, family history or long QT syndrome)

5. Uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg confirmed upon repeated measures

6. Left ventricular ejection fraction <50% as determined by echocardiogram (ECHO) performed at screening or within 30 days prior to C1D1

7. QT/QTc interval >480 msec, before C1D1 treatment administration, as determined by screening electrocardiogram (ECG)

8. Received anti-tumor therapy (chemotherapy, investigational product, radiotherapy, retinoid therapy, or hormonal therapy) within 2 weeks (less than 14 days) prior to C1D1 with no residual toxicity >Grade 1; antibody therapy, molecular targeted therapy within 5 half-lives prior to C1D1

9. Major surgery within 4 weeks (less than 28 days) prior to C1D1

10. Active joint inflammation or other immune disorder involving joints (osteoarthritis is not exclusionary)

11. Active infection involving IV antibiotics within 2 weeks prior to C1D1

12. Positive serology test for hepatitis B virus (HBV), hepatitis C virus (HCV), or active tuberculosis

13. Positive serology test for human immunodeficiency virus (HIV) type 1 and 2, or known history of other immunodeficiency disease

14. Participant has received a live vaccine within 2 weeks (less than 14 days) prior to C1D1

15. Known hypersensitivity to any component of recombinant protein production by Chinese Hamster Ovary (CHO) cells

16. Any disorder or disease, or clinically significant abnormality on laboratory or other clinical test(s) (eg, blood tests and ECG), that in medical judgment of the investigator may impede the participant's participation in the study, pose increased risk to the participant, and/or confound the results of the study

17. Participant is a family member or employee of the investigator

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Baxalta now part of Shire

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director

Role: STUDY_DIRECTOR

Shire

Locations

University of Miami Miller School of Medicine

Miami, Florida, United States

Georgia Regents University

Augusta, Georgia, United States

Women's Health Specialists

Silver Spring, Maryland, United States

Montefiore Medical Center

The Bronx, New York, United States

Stephenson Cancer Center at The University of Oklahoma

Oklahoma City, Oklahoma, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Countries

United States

Other Identifiers

2015-003492-29

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

391402

Identifier Type: -

Identifier Source: org_study_id